Helixgate

Helixgate

Uncategorized

Soleno sold at a discount to Neurocrine due to dwindling European prospects

Soleno sold at a discount to Neurocrine due to dwindling European prospects

Published

on

The bleak European approval potential for Soleno Therapeutics’ genetic obesity drug essentially forced the US drugmaker to sell itself for less than it was once worth.

In a rare case, Soleno sold at a price …​ ​Read More

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Uncategorized

STAT+: Kelonia Therapeutics’ road from floundering to $3 billion

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Good morning. Starting and sustaining a biotech company is never easy. If you need a reminder on that, read to the end of today’s newsletter.

BioAge’s bet on inflammation shows early promise

BioAge is making its way into the race among drug companies to target inflammation as a way to treat chronic conditions.

Continue to STAT+ to read the full story…

Read More

Published

on

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Good morning. Starting and sustaining a biotech company is never easy. If you need a reminder on that, read to the end of today’s newsletter.

BioAge’s bet on inflammation shows early promise

BioAge is making its way into the race among drug companies to target inflammation as a way to treat chronic conditions.

Continue to STAT+ to read the full story…

Read More

Continue Reading

Uncategorized

Merck, Eisai’s Keytruda triplet fails to improve survival in kidney cancer

Published

on

A triplet regimen comprising Merck’s Welireg and PD-1 blockbuster Keytruda and Eisai’s Lenvima flopped in a Phase 3 renal cell carcinoma trial.

Continue Reading

Uncategorized

AACR 2026: Moderna, Revolution, Zymeworks and BeOne showcase new data

Published

on

Moderna, Revolution Medicines and Zymeworks record wins in melanoma, lung and breast cancers, while BeOne swings and misses at head and neck cancer.

Continue Reading
Advertisement

Trending